Publications

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).
Genes Chromosomes Cancer 2017 Oct 24;56(10):719-729. Epub 2017 Jul 24.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
J Urol 2017 Sep 31;198(3):583-590. Epub 2017 Mar 31.
Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
Clin Nucl Med 2017 Aug 12. Epub 2017 Aug 12.
From the *Molecular Imaging Program, National Cancer Institute, Bethesda; †Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick, MD; ‡Institute of Diagnostic Radiology, Department of Medical Area, University of Udine, Udine, Italy; §Office of the Clinical Director/Center for Cancer Research/National Cancer Institute, Bethesda; ∥Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick; ¶Office of the Pharmaceutical Quality, FDA/CDER, Silver Spring; **Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore; ††Laboratory of Pathology, National Cancer Institute, Bethesda; ‡‡Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville; §§Center for Interventional Oncology, National Cancer Institute and Clinical Center, and Radiology Imaging Sciences, National Institutes of Health, Bethesda; and ∥∥Urologic Oncology Branch, National Cancer Institute, Bethesda, MD.

Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?
Urology 2017 Jul 15;105:113-117. Epub 2016 Nov 15.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.
Radiology 2017 Jul 19:161316. Epub 2017 Jul 19.
From the Molecular Imaging (M.D.G., F.V.M., P.L.C., B.T.) and Biometric Research (J.H.S.) Programs, Laboratory of Pathology (M.J.M.), and Urologic Oncology Branch (P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, Room B3B85, Bethesda, MD 20892; Imaging Biomarkers and Computer-Aided Diagnosis Laboratory, Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Md (N.L., R.M.S.); Department of Radiology, University of Cambridge School of Medicine, Cambridge, England (T.B.); Department of Radiology, Universidade Federal Fluminense, Rio de Janeiro, Brazil (L.K.B.); Department of Body Imaging, CDPI Clinics/DASA, Rio de Janeiro, Brazil (L.K.B.); Department of Radiology, George Washington University Hospital, Washington, DC (S.B.); Department of Radiology, Hacettepe University, Ankara, Turkey (I.M.K.); Department of Diagnostic Radiology Singapore General Hospital, Singapore (Y.M.L.); Department of Radiology, Walter Reed National Military Medical Center, Bethesda, Md (J.M.); Department of Radiology, Nephrology Center, Mansoura University, Mansoura, Egypt (H.S.); Center for Interventional Oncology, National Cancer Institute and Clinical Center, and Radiology Imaging Sciences, National Institutes of Health, Bethesda, Md (B.J.W.).

Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.
Genes Chromosomes Cancer 2017 Jun 31;56(6):484-492. Epub 2017 Mar 31.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.





Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Clin Cancer Res 2016 Oct;22(20):4989-5000
James J. Peters Veterans Administration Medical Center, Bronx, New York. Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, New York, New York.

Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
J Urol 2016 Sep 18;196(3):690-6. Epub 2016 Apr 18.
Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.
J Natl Cancer Inst 2016 Sep 29;108(9). Epub 2016 Apr 29.
Urologic Oncology Branch (MMS, AKG, RR, SRB, BJW, PAP), Molecular Imaging Program (BT, PLC), Division of Cancer Prevention (HLP), Laboratory of Pathology (MJM), and Center for Interventional Oncology, Department of Radiology and Imaging Sciences (BJW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, MD; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, MD (RMS); Department of Surgery, Division of Urology, University of Maryland, Baltimore MD (MMS); Departments of Urology and Radiology, University of Alabama at Birmingham, Birmingham, AL (SRB)

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Int Urol Nephrol 2016 Sep 15;48(9):1445-52. Epub 2016 Jun 15.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 1-5940, 20892, Bethesda, MD, USA.




Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.
Top Magn Reson Imaging 2016 Jun;25(3):139-47
*Molecular Imaging Program, NCI, NIH, Bethesda, MD †Department of Radiology, George Washington University Hospital, Washington, DC ‡Hacettepe University, School of Medicine, Department of Radiology, Ankara, Turkey §Laboratory of Pathology, NCI ¶Center for Interventional Oncology, NCI and Radiology and Imaging Sciences, Clinical Center ||Urologic Oncology Branch, NCI, NIH, Bethesda, MD.


Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging.
J Comput Assist Tomogr 2016 Mar-Apr;40(2):218-24
From the *Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; †iCAD, Inc, Nashua, NH; ‡Division of Cancer Treatment and Diagnosis, Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; §Imaging Physics, SAIC Frederick, Inc, National Cancer Institute-Frederick, Frederick, MD; and ∥Laboratory of Pathology, ¶Center for Interventional Oncology, and #Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.


Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Proc Natl Acad Sci U S A 2016 Feb 10;113(8):2170-5. Epub 2016 Feb 10.
Department of Pathology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095;

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
N Engl J Med 2016 Jan 4;374(2):135-45. Epub 2015 Nov 4.

PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Abdom Radiol (NY) 2016 Jan;41(1):109-18
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2 W-5940, 10 Center Drive, MSC 1210, Bethesda, MD, 20892-1210, USA.

Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.
Radiology 2015 Dec 18;277(3):741-50. Epub 2015 Jun 18.
From the Molecular Imaging Program (B.G.M., S.S., P.L.C., B.T.), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (J.H.S.), Urologic Oncology Branch (S.R.B., A.G., P.P.), Laboratory of Pathology (M.J.M.), and Center for Interventional Oncology (B.J.W.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Room B3B85, Bethesda, MD 20892-1088; Department of Urology, AMC University Hospital, Amsterdam, the Netherlands (B.G.M., J.J.M.C.H.d.l.R.); and Department of Radiology and Radiological Sciences, Edward Hébert School of Medicine, Uniformed Services University of The Health Sciences, Bethesda, Md (J.M.).

Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations.
Am J Surg Pathol 2015 Nov;39(11):1488-92
*Translational Surgical Pathology Section, Laboratory of Pathology, National Cancer Institute †Eunice Kennedy Shriver, National Institute of Child Health and Human Development ‡Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.



The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy.
J Urol 2015 Jul 23;194(1):105-111. Epub 2015 Jan 23.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address:


Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
N Engl J Med 2015 Jul;373(5):448-55
From the Endocrine Oncology Branch (S.K.G., L.Z., D.P., E.K.), Bioinformatics Core (L.J.) and Laboratory of Pathology (M.J.M.), Center for Cancer Research, and the Office of Science and Technology Resources (M.C.), National Cancer Institute, and the Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (S.K.A.) - both in Bethesda, MD.


Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.
Urol Oncol 2015 May 6;33(5):202.e1-202.e7. Epub 2015 Mar 6.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:


Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
Proc Natl Acad Sci U S A 2015 Mar 16;112(13):E1624-31. Epub 2015 Mar 16.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702

The role of image guided biopsy targeting in patients with atypical small acinar proliferation.
J Urol 2015 Feb 20;193(2):473-478. Epub 2014 Aug 20.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address:

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
JAMA 2015 Jan;313(4):390-7
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland6Center for Interventional Oncology, Department of Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes.

Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
J Urol 2014 Dec 9;192(6):1642-8. Epub 2014 Aug 9.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address:


A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Breast Cancer Res Treat 2014 Nov 26;148(1):99-106. Epub 2014 Sep 26.
Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, Indianapolis, IN, 46202, USA,


Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int J Cancer 2014 Aug 22;135(4):862-70. Epub 2014 Feb 22.
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression.
J Comput Assist Tomogr 2014 Jul-Aug;38(4):565-7
*From the Molecular Pharmacology Section, Medical Oncology Branch, and †Molecular Imaging Program, National Cancer Institute, Bethesda, MD; ‡Urologic Oncology Branch, NCI, NIH, Bethesda, MD; §Center for Interventional Oncology, Radiology and Imaging Sciences CC, NIH, Bethesda, MD; ∥Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and ¶Laboratory of Pathology, NCI, NIH, Bethesda, MD.





Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
Radiology 2014 Mar 8;270(3):849-56. Epub 2013 Nov 8.
From the Molecular Imaging Program (B.T., E.M., M.L.L., M.B., Y.L.M., S.A., P.L.C., K.A.K.), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (J.S.), Urologic Oncology Branch (P.A.P.), and Laboratory of Pathology (M.J.M.), National Institutes of Health, National Cancer Institute, 10 Center Dr, MSC 1182 Bldg 10, Room B3B85 Bethesda, MD 20892-1088; and Medical Diagnostics Research and Development, GE Healthcare, Uppsala, Sweden (R.O.).

Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy.
J Comput Assist Tomogr 2014 Mar-Apr;38(2):274-6
From the *Urologic Oncology Branch, †Laboratory of Pathology, ‡Molecular Imaging Program, and §Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.
J Clin Endocrinol Metab 2014 Feb 11;99(2):E329-37. Epub 2013 Dec 11.
Endocrine Oncology Branch (R.J.E., M.B., D.P., N.N., M.H., L.Z., E.K.), Genetics Branch (Y.W., H.S.S., S.D., D.C.E., P.S.M.), and Laboratory of Pathology (M.J.M.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; and Perelman School of Medicine (R.J.E.), University of Pennsylvania, Philadelphia, Pennsylvania 19104.

Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates?
J Urol 2013 Dec 18;190(6):2020-2025. Epub 2013 Jun 18.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.
J Urol 2013 Nov 29;190(5):1721-1727. Epub 2013 May 29.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address:

Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
Eur Urol 2013 Nov 12;64(5):713-719. Epub 2013 Jun 12.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Fully automated prostate segmentation on MRI: comparison with manual segmentation methods and specimen volumes.
AJR Am J Roentgenol 2013 Nov;201(5):W720-9
1 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B69, Bethesda, MD 20892-1088.

Renal tumors: diagnostic and prognostic biomarkers.
Am J Surg Pathol 2013 Oct;37(10):1518-31
*Department of Pathology, Singapore General Hospital, Singapore, Singapore †Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN §Laboratory of Pathology, National Cancer Institute, Bethesda ∥Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD ¶Memorial Sloan Kettering Cancer Center, New York, NY #Department of Pathology and Genomic Medicine, The Methodist Hospital and Weill Medical College of Cornell University, Houston, TX ‡Service d'Anatomie et Cytologie Pathologiques, CHU Pontchaillou, Rennes, France **Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Ancona, Italy ††Karolinska Institute, Stockholm, Sweden ‡‡Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada §§Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand ∥∥Institute of Surgical Pathology, University of Zurich, Zurich, Switzerland.


Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol Immunother 2013 Sep 9;62(9):1521-31. Epub 2013 Jul 9.
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 8B09 MSC 1750, Bethesda, MD 20892, USA.


Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?
Radiology 2013 Jul 6;268(1):144-52. Epub 2013 Mar 6.
Molecular Imaging Program, Laboratory of Pathology, Radiation Oncology Branch, and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182 Bldg 10, Room B3B69, Bethesda, MD 20892-1088, USA.





Correlation of magnetic resonance imaging tumor volume with histopathology.
J Urol 2012 Oct 15;188(4):1157-1163. Epub 2012 Aug 15.
Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland; Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address:

Characterization and management of testicular pathology in McCune-Albright syndrome.
J Clin Endocrinol Metab 2012 Sep 28;97(9):E1782-90. Epub 2012 Jun 28.
Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA.


Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer.
Urology 2012 Jan;79(1):233-9
Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, Molecular Imaging Program, Urologic Oncology Branch, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1088, USA.

OF